Table 1.
Patient characteristics.
|
All (n = 40) |
Dabigatran (n = 10) |
Rivaroxaban (n = 12) |
Apixaban (n = 9) |
Edoxaban (n = 9) |
|
|---|---|---|---|---|---|
| Medication dose: n | 300 mg:5, 220 mg:5 | 15 mg:12 | 10 mg:9 | 60 mg:7, 30 mg:2 |
|
| Age, years | 58 ± 13 | 59 ± 12 | 51 ± 14 | 61 ± 13 | 63 ± 8 |
| Male, n (%) | 34 (85) | 10 (100) | 11 (92) | 7 (78) | 6 (67) |
| LVEF, % | 63 ± 11 | 57 ± 14 | 66 ± 7 | 59 ± 10 | 68 ± 5 |
| LAD, mm | 38 ± 5 | 39 ± 5 | 37 ± 6 | 37 ± 5 | 39 ± 5 |
| Persistent AF, n (%) | 15 (38) | 5 (50) | 2 (17) | 6 (67) | 2 (22) |
| Median CHADS2 Score | 0.5 ± 0.6 | 0.6 ± 0.7 | 0.3 ± 0.4 | 0.3 ± 0.5 | 0.9 ± 0.6 |
| CHF, n (%) | 1 (3) | 1 (10) | 0 | 0 | 0 |
| Hypertension, n (%) | 15 (38) | 3 (30) | 3 (25) | 3 (33) | 6 (67) |
| Age ≥ 75 years, n (%) | 2 (5) | 1 (10) | 0 | 0 | 1(11) |
| Diabetes mellitus, n (%) | 1 (3) | 1 (10) | 0 | 0 | 0 |
| Stroke/TIA, n (%) | 0 | 0 | 0 | 0 | 0 |
| History of MI | 0 | 0 | 0 | 0 | 0 |
| Smoking, n (%) | 16 (40) | 2 (20) | 4 (33) | 5 (56) | 4 (44) |
| Current smoker | 2 (5) | 0 | 1 (8) | 1 (11) | 0 |
| Ex-smoker | 14 (35) | 2 (20) | 3 (25) | 4 (44) | 5 (56) |
| Antiplatelet drug, n (%) | 0 | 0 | 0 | 0 | 0 |
| Statin, n (%) | 3 (8) | 1 (10) | 0 | 0 | 2 (22) |
LVEF, left ventricular ejection fraction; LAD, left atrial diameter; AF, atrial fibrillation; CHF, congestive heart failure; TIA, transient ischemic attack; MI, myocardial infarction